Month: 2025-04

香港, 2025年3月31日 - (亞太商訊 via SeaPRwire.com) - 華泰證券3月28日公告，2024年公司實現營業收入人民幣（下同）542.85億元，歸屬於本公司股東的本年利潤153.51億元。公司宣佈每10股派息3.7元（含稅），2024年累計分紅46.94億元。2024年，華泰證券保持以客戶為中心、科技賦能財富管理和機構服務的戰略定力，積極把握資本市場深化改革和金融高水平開放的戰略機遇，依託一體化、全業務鏈協同，深化國際化戰略佈局，資產規模與盈利能力穩居行業頭部。切實服務科技創新 科創板、創業板IPO躋身行業首位資本市場對促進產業和科技創新具有獨特而重要的支撑作用。作為中介機構，公司始終以服務國家戰略為己任，致力於提供與科技創新、產業發展周期各階段相適應的全業務鏈服務。2012年至2024年末，本集團累計服務科技創新企業超過270家，總市值約9.47萬億元。公司聚焦企業全生命周期需求，構建覆蓋TMT、大健康、高端製造等核心產業的金融服務體系，提供IPO、併購重組、資產證券化等一體化解决方案。2024年，公司股權主承銷規模549億元，其中A股IPO主承銷規模85.38億元，排名行業第二，科創板、創業板IPO主承銷規模均躋身行業第一；全品種債券主承銷規模12,960億元，排名行業第三；公司擔任獨立財務顧問的審核類重組項目首次披露數和獲監管受理數均位列行業第一。私募股權投資領域新增投資項目中，國家級專精特新小巨人企業與專精特新中小企業的數量超過10家。縱深拓寬全球金融服務體系 新興市場佈局加速近年來，華泰證券國際業務有效應對境外市場複雜多變的衝擊，保持逆市穩進，參與打造一系列港美股明星項目，綜合實力穩居香港中資券商頭部，2024年公司港股IPO保薦家數位列行業第三、保薦承銷規模位列中資券商第三。伴隨中國企業的全球化佈局展業，公司對標國際一流投行深入推進業務板塊和業務能力的全球化，在中國內地及香港、美國、英國、新加坡等多地聯動的基礎上，積極拓展國際業務佈局。2024年，華泰金控（香港）登記為東京PRO-BOND市場主承銷商；華泰證券（美國）新獲美國納斯達克證券交易所有限承銷會員資格；華泰國際旗下子公司以中資券商身份，於越南證券市場監管機構成功獲批證券交易代碼。國際業務的高效開展需要全球視角下的技術平台支撑，公司積極推進境內外一體化的下一代交易系統建設，自主研發的全球交易平台（GTP）已正式投入運營，24小時連接中國香港、美國、英國、新加坡市場。機構業務平台行知全面升級華泰海外研究和海外站，以國際化視野、前瞻性思維提供海外研究產品。2024年研究所共出具海外研報587篇，同比增長96%，研究範圍涵蓋美國、歐洲、日本、東南亞等多個區域；截至2024年底，覆蓋的美股、日股、韓股總數同比增長65%。主動適應變化 科技牽引業務轉型升級2024年，證券行業發展邏輯深刻變化，華泰證券堅持以科技賦能業務轉型，用平台高效連接資產、客戶與產品，推動機構服務能力升級。FICC全球一體化交易平台（HEADS）、信用分析管理平台（CAMS）等核心交易平台持續迭代，强化定價與交易服務優勢，實現從規模增長向能力產品化的轉型。機構客戶服務競爭力顯著提升，公募保險客戶排名持續領先。截至2024年底，科創板股票做市數量達126隻，上市基金做市服務覆蓋589隻ETF基金，均居行業前列；港幣-人民幣雙櫃檯做市業務實現標的全覆蓋，成交量市佔率顯著提升，獲頒港交所「2024年最活躍莊家 - 人民幣櫃檯」獎項。依託大語言模型與金融中台，公司持續構建智能化服務體系。「漲樂財富通」深化AI應用，優化ETF投資工具，推動客戶規模和資產規模增長。2024年下半年，公司權益基金保有規模、非貨幣市場基金保有規模、股票型指數基金保有規模分別為1,202億元、1,666億元、1,087億元，均排名證券行業第二，並躋身基金代銷總榜前十。華泰柏瑞滬深300ETF規模近3,600億元，穩居滬深兩市非貨幣ETF市場第一。此外，公司成為首批「跨境理財通2.0」試點券商，拓展全球化配置服務。華泰證券不斷提升自身治理水平，積極踐行可持續發展理念，2024年MSCI ESG評級從AA級躍升至AAA級，連續兩年實現進階，達到全球投資銀行業最高評級。公司依託華泰公益基金會，在鄉村振興、教育醫療、生態環境保護等領域持續加大投入，通過「一個長江」生態環境保護項目支持徵集中國OECM（其他有效的區域保護措施）潛力案例，在聯合國生物多樣性公約COP16大會上發佈，展示中國社會多元力量支持可持續發展的雄心。憑藉務實專業的項目管理和規範高效的內部治理，華泰公益基金會2024年首次參與江蘇省社會組織等級評估即獲得5A的最高評級。 Copyright 2025 亞太商訊 via SeaPRwire.com.

HONG KONG, Mar 31, 2025 - (ACN Newswire via SeaPRwire.com) - Yunkang Group Limited ("Yunkang" or the "Group"; Stock Code: 2325), a leading medical operation services provider in China, has announced its annual results for the year ended December 31, 2024 (the "Reporting Period"). During the year, the Group adhered to its overall business philosophy of “in-depth services and lean operations”, promoted development with innovation, deepened integrated collaboration among “government, industry, academy, research, medicine, application”, accelerated digital application of “AI + medical care”, continuously strengthened refined management, and reduced cost and improved efficiency, demonstrating strong operational resilience.In 2024, due to changes in the macro-environment, intensified competition in the industry as well as its strategic decision to optimize customer structure and product mix, the Group’s performance was temporarily affected. However, relying on its customer-oriented, innovative and coordinated development system, the Group achieved many breakthroughs in product innovation, model innovation, AI + medical digital intelligence and other aspects. The joint construction business with medical institution alliances remained its largest business segment, which accounted for 53.0% of the total revenue, representing an increase of 4.7 percentage points as compared to the same period of the previous year. In addition, featured products in the infection segment achieved rapid growth, laying a solid foundation for the segment’s long-term development. During the Reporting Period, the Group’s total revenue reached RMB711.9 million.Diagnostic testing for medical institution alliances was developing healthily In-depth service empowers customersYunkang is committed to developing an innovative service mode for joint construction of medical institution alliances with “professionalism as the foundation, standardization as the core, digital intelligence as the means, synergization as the goal”. At present, the Group is providing medical technical service solutions to over 1,500 medical institutions in collaboration with medical institution alliances at over 430 on-site diagnostic centers of the alliances to meet their core demands. Through close collaboration – mutual recognition of testing results – with leading regional medical institutions, the Group has helped improve overall regional medical and treatment levels, helping hospitals build specialty departments, improving the efficiency of hierarchical diagnosis and treatment, promoting scientific research and cooperation, etc., thereby providing the public with higher-quality and more efficient diagnosis and treatment services. Dedicated to vigorously driving medical reform in China, during the Reporting Period, Yunkang teamed up with leading provincial-level hospitals, and regional county-level general hospitals to jointly build medical institution alliances to actively promote the construction of medical institution alliances as the bridge that connects the regional testing centers and partner hospitals. Customers are provided with “3+N” tumor, infection, reproductive genetics and +N technical system support, and also support from the in-depth service system, including the operation of diagnostic centers under regional medical institution alliances, access to new technologies or new products, construction services for digital specialty departments, medical cold chain logistics services, quality control services and supply chain services, all in-depth services for empowering demand and the long-term development of hospitals.Focus on “clinical demands” Joint innovation for diagnostic testing achieved remarkable resultsAdhering to the “clinical demands”-oriented service concept, the Group has built a series of high-tech platforms, including high-throughput sequencing, gene chip, high-sensitivity PCR, protein spectrometry, cytogenetics, digital remote pathology, and ultra-micro pathology. During the Reporting Period, the Group introduced nearly 800 new testing items and provided about 3,800 clinical testing items, and more than 10 million specimens were tested for the year. In terms of precision diagnosis and treatment, the Group carried out more than 500 precision diagnosis services using cutting-edge technologies such as high-throughput sequencing, and protein spectrometry, covering five medical fields including infectious diseases, reproductive genetics, solid tumors, blood diseases, and personalized medicine. During the Reporting Period, the Group focused on the construction and development of 58 new items in such fields including infection, tumor, rare genetic diseases and personalized medicine, providing medical institutions nationwide with a more comprehensive range of precision diagnosis solutions to drive the embrace and development of precision medicine. During the Reporting Period, revenue from special testing items increased significantly year-on-year, accounting for a larger percentage of the Group’s overall revenue.The Group has a first-of-its-kind “joint innovation platform for diagnostic testing”, which has played a vital role in expanding its business and boosting competitiveness of its products. Constantly exploring and putting ideas into practice, the Group and dozens of top medical institutions across the country have pursued joint innovation for diagnostic testing and successfully developed more than 10 testing products for different infection syndromes in various fields such as respiratory tract infections and central nervous system infections.Digital application of “AI + medical care” leads the industryThe Group has launched and continuously upgraded its top 10 digital “cloud” systems, covering core areas such as laboratory operations, sales management, human resources, staff training, and customer services. At the same time, it has integrated AI technology into its “cloud” systems to create a one-stop intelligent medical diagnostic solution covering from “sample collection” to “report delivery”, which was comprehensively applied across its multi-technology platforms in medical laboratories, with the core concepts of “Internet+” and “precision diagnosis” to create a series of intelligent diagnostic platforms. In the Reporting Period, the Group’s self-developed digital IT platform with full intellectual property rights – the remote pathology consultation platform – covered over 800 medical testing items, assisting nearly 300 medical institutions nationwide in enhancing their pathology diagnostic capabilities and benefiting more than 200 million patients in rural areas.Regarding the application of AI-assisted diagnosis, the Group adheres to the strategy of “introducing one item once it is mature” and closely follows industry development trends. It has introduced items such as pathological DNA polyploid AI-assisted diagnosis, cervical liquid-based cell AI-assisted diagnosis, and chromosome AI analysis, all proven effective and have greatly enhanced diagnostic efficiency. During the Reporting Period, the Group focused on the field of infectious diseases and developed its first infectious disease data product, the “Yunkang Respiratory Pathogen Detection Positivity Rate Analysis Report”. The product officially obtained data product certification and was listed on the Guangzhou Data Exchange in January 2025, marking a milestone step for the Group in the field of compliant data transactions, effectively unlocking data value. Currently, having access to the DeepSeek large model, the Group aims to achieve comprehensive innovation in medical testing and diagnostics through inclusive technology, precision service and intelligent management.Collaborative and integrated development of “government, industry, academy, research, medicine, application” to facilitate industrial upgradeDuring the Year, the Group collaborated with various institutions to facilitate industrial upgrade based on a unique innovative industrial model, including:- Collaboration with The People’s Government of Ouhai, Wenzhou City and Wenzhou Medical University’s core areas in biomedical industry to promote construction of a number of key projects including a joint innovation and transformation platform, a public service platform, a medical big data research platform, a regional diagnostic sharing center and a training base for innovative talent, to the end of facilitating quick transformation of scientific research results for industrial applications;- Collaboration with The Zhangjiang Research Institute of Fudan University to jointly establish a “Collaborative Innovation and Transformation Center” to promote innovation and transformation of results of medical diagnostic technology application;- Collaboration with The Central University of Finance and Economics, Greater Bay Area Research Institute to jointly build an industry-education fusion talent cultivation highland and an industry aggregation and incubation platform.The strategy for sustainable development drives long-term valueWhile vigorously driving business development, Yunkang has consistently viewed sustainable development as a core strategy of the Group, committed to promoting the green transformation of the healthcare industry through innovative technologies and in-depth services. The Group engaged in environmental protection efforts such as energy conservation, emission reduction, and resource recycling in its operations, while also launched various charitable initiatives, including charitable clinical diagnostic activities, health checkup services for the well-being of the community, and health seminars, to give back to society by making use of its professional advantages. Looking ahead, Yunkang will continue to make progress in ESG and step up our efforts in such areas as environmental policy and management, Scope 3 emissions, climate governance, climate performance indicators, climate scenario analysis, carbon reduction targets, and net-zero emissions commitment, all of which will help us realize economic, environmental and social benefits.Future prospectsChina has continued to promote expansion and downward penetration of the country’s high-quality medical resources, fostering a balanced regional layout and stepping up the construction of a hierarchical diagnosis and treatment system, conducive to establishing close-knit medical institution alliances. China’s Laboratory Developed Testing methods (LDT) pilots have steady and notable progress, leading to market growth for precision medicine development. In addition, in-depth integration of AI technology with the healthcare industry will become an important driving force for fine industry segments to embark on digital intelligence transformation and upgrade. Looking ahead, Yunkang will continue to align with national policies, seize the latest industry development opportunities, and continue to strengthen clinical-empowered value, and constantly explore and deepen the two new “product innovation + model innovation” model with customers in mind and to ensure residents can better benefit from its medical achievements.Yunkang Group Limited（Stock Code：2325）Yunkang Group is a leading medical operation service provider in China, which started to provide standardized medical diagnostic services to medical institutions at all levels as early as 2008. Leveraging its own professional diagnostic capabilities and the nationwide service network of integrated healthcare systems, Yunkang has gradually grown to become a medical operation service platform. Meanwhile, Yunkang is a medical operation service provider in China offering a full suite of diagnostic testing services which are diagnostic outsourcing services and diagnostic testing services for medical institution alliances. Yunkang provides diagnostic services through on-site diagnostic centers to collaborative hospitals in the integrated healthcare systems in China and assists them in improving their clinical diagnosis capabilities through co-developing diagnostic centers. As of today, Yunkang has successfully provided professional services to 430+ on-site diagnostic centers. As of December 31, 2024, the hospitals we collaborated with were located across 31 provinces and municipalities in China. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Apr 4, 2025 - (ACN Newswire via SeaPRwire.com) - Connect Marketplace Hong Kong (CMHK) successfully concluded its preview event in APAC in 2025, marking a significant milestone in fostering business collaboration within the MICE industry. Held from 19-21 March 2025, the event successfully brought together over 4,000 industry professionals, along with more than 60 exhibitors from over 30 countries and regions. It focused on creating an invaluable platform for networking and business development.Margaret Ma Connolly, president and CEO of Informa Markets in Asia, highlighted the event’s role in driving transformation within the MICE industry. “The launch of Connect Marketplace Hong Kong is more than just a new event. It's a testament to our belief in Hong Kong as the ultimate MICE destination. Here at Connect Marketplace Hong Kong, we’re not just discussing the future of business events – we’re actively shaping it, fostering connections that transcend borders and drive economic growth across Asia and beyond” she said.Connect Marketplace Hong Kong excelled as a premier platform for business collaboration, featuring the Hosted Buyer Programme, which brought together around 450 international decision-makers and facilitated close to 1,300 business organised through its innovative one-on-one meeting initiatives.Additionally, conference sessions and forums addressed key industry topics, from sustainability to cutting edge MICE solutions. A series of networking opportunities, including Horse Racing Night, Gala Dinner and a Familiarization Trip to Macau further strengthened interactions among global industry players.Janice Lee, Senior Portfolio Director of Connect Marketplace Hong Kong, expressed excitement for future growth: “This is a remarkable achievement! I have witnessed the spirit of Informa unfold over four months of hard work, culminating in around 4,000 attendees at the show. This success gives us great confidence as we look ahead to the next edition of CMHK in 2026.” The next edition of Connect Marketplace Hong Kong is scheduled for 18-19 March 2026.About Informa MarketsInforma Markets creates platforms for industries and specialist markets to trade, innovate and grow. Our portfolio is comprised of more than 550 international B2B events and brands in markets including Healthcare & Pharmaceuticals, Infrastructure, Construction & Real Estate, Fashion & Apparel, Hospitality, Food & Beverage, and Health & Nutrition, among others. We provide customers and partners around the globe with opportunities to engage, experience and do business through face-to-face exhibitions, specialist digital content and actionable data solutions. As the world’s leading exhibitions organiser, we bring a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year. For more information, please visit www.informamarkets.com.For media enquiries, please contact: cheenie.so@informa.com Copyright 2025 ACN Newswire via SeaPRwire.com.

HIGHLIGHTS:- During the Reporting Period, the Group’s gross billings amounted to approximately RMB3,505.9 million, representing an increase of approximately 49.3% from approximately RMB2,347.7 million for the Corresponding Period.- The total revenue of the Group was approximately RMB2,306.0 million, representing an increase of approximately 17.3% compared to approximately RMB1,965.4 million for the Corresponding Period.- The profit attributable to Shareholders of the Group was approximately RMB272.4 million, representing an increase of approximately 42.8% from approximately RMB190.7 million for the Corresponding Period.- The Group’s operating cash flow (net inflow) was approximately RMB1,627.8 million, representing an increase of approximately 266.6% as compared to approximately RMB444.0 million for the Corresponding Period.- Taking into account the financial and cash flow positions of the Group, the Board recommends the payment of a final dividend of approximately HKD148.0 million for the year ended December 31, 2024, representing HKD0.33 per share (in cash), and the proposed final dividend is subject to consideration and approval by Shareholders at the AGM.HONG KONG, Apr 4, 2025 - (JCN Newswire via SeaPRwire.com) - 28 March, JF SmartInvest Holdings Ltd(the “Company” ; together with its subsidiaries, the "Group" or “we”) is pleased to announce its consolidated annual results for the year ended December 31, 2024 (the “Reporting Period”). During the Reporting Period, the Company realized a revenue of approximately RMB2,306.0 million, representing a growth of approximately 17.3% from the Corresponding Period. Profit attributable to Shareholders amounted to approximately RMB272.4 million, representing an increase of 42.8% over the Corresponding Period. In addition, our operating cash flow was strong. We had a net inflow of approximately RMB1,627.8 million which represented a significant year-on-year growth of 266.6%, fully demonstrating the effective strategy execution and high market adaptability of the Company.Developed a multi-dimensional product structure to promote business and revenue diversificationDuring the Reporting Period, on top of integrating and improving our existing products, we launched the industry’s first-ever stock learning machine and enriched our small-amount series product matrix for the promotion of revenue diversification. We have formed four main product lines currently, namely “Stock Navigator Series and Super Investor” , “Enjoy-Stock Pad”, “Jiuyao Stocks” and “SmartInvest App” (App). We aim to serve a wider spectrum of customers in a more effective manner by capitalizing on the synergies of these product lines.In order to meet users’ needs, we launched the first “Enjoy-Stock Pad (Starter Edition)” in July to fill the market gap for professional stock learning products. The Company expected that the launch of this product would create a dedicated learning platform for investors, actively fulfil corporate social responsibilities and deepen the inclusive financial education practice. In the meantime, we launched nearly 30 lightweight products to achieve product scalability and standardization, which allowed us to meet the diverse users’ needs and fully explore long-tail customers. During the Reporting Period, our small-amount series products were used by our subscriber customers for more than 2.203 million times.Adherence to pursuing “technological research + investment research” dual-driver strategy, deepening AI technology for full empowerment for the Company’s business and practical applicationImplementing our “technology + investment research” dual-driver strategy, we further increased our R&D investment, explored the empowerment and application of AI and other frontier technologies to the Company’s product offerings, business operations and operational management. With focus on the “buyer-side investment advisory” service, we strengthened our “1+N” investment research system to fully penetrate our investment research into businesses and processes, so as to professionally support our customers in creating long-term value.We continuously strengthened our R&D capabilities and investment: During the Reporting Period, we invested approximately RMB319 million in R&D activities, representing an increase of 10.9% over the Corresponding Period. Such R&D investment accounted for approximately 13.8% of the Company’s total revenue. In addition, as of the end of the Reporting Period, we had 136 software copyrights and patents on product features, big data and AI, that was 52 more than last year. What is noteworthy is that during the Reporting Period, we became a member of the Chinese Association for Artificial Intelligence (CAAI), signifying that the Company has been recognized for its core AI R&D technologies and achievements in the financial sector.We explored the all-round empowerment of AI and other frontier technologies to the Company’s product offerings, business operations and operational management. In terms of empowering our product offerings, we launched “FinSphere Agent”, a new-generation conversational stock investing assistant, and “FinSphere Report”, an intelligent investment research product. They provide deep-thinking intelligent conversational investment advisory services and intelligent research report generation and explanation services. We continuously upgraded our digital investment robo-advisor “Jiu Ge”, served approximately 472,000 customers, with total services reaching 32.407 million times, during the Reporting Period. In terms of empowering our business operations, we deployed our “AI Marketing Partners” and “AI Live Replay Summaries” which enabled us to achieve full-process coverage of text generation and pitch recommendations that doubled our communication efficiency. In terms of empowering our compliance management: The Company developed the intelligent compliance management solution 3.0, with which, our “AI Monitoring Officer” has conducted approximately 1.6 billion monitoring tasks and our “AI Inspection Officer” has assisted in over 10 million review tasks, achieving a coverage rate of 98%.We focused on “buyer-side investment advisory” and emphasized the application of our investment research. In the single month of December, our professional stock review programs output an average of approximately 22 shows per day, with a total duration of nearly 13 hours; we engaged active interactions with investors and answered their questions. The average number of inquiries per day exceeded 2,500. Our JF Financial Research Institute has designed more than 218 sets of self-developed signature courses, with a total of more than 1,300 sessions and a total of over 12,000 minutes, further improving the system of providing courses on our Stock Learning Machine.Establishment of quality traffic system to achieve precise expansion of new customer baseWe established quality traffic system and continued to expand our presence on platforms. During the Reporting Period, apart from our established presence on Douyin and WeChat Channels, we explored Kuai and tapped into platforms such as Xiaohongshu and Bilibili, to achieve high accessibility to customers, increase our brand exposure, optimize our live broadcast efficiency and enhance viewers’ experience through short video + live broadcast approach. The live broadcasts lasted over 49,800 hours cumulatively with 26,500 sessions, representing a growth of over 110% from the Corresponding Period. During the Reporting Period, we operated 152 new MCN accounts on different internet platforms. As of December 31, 2024, we had 526 MCN accounts and attracted approximately 50.05 million followers, as compared to approximately 11.15 million followers in the Corresponding Period.At the same period, we actively promoted popular investor education and enhanced brand influence. At the National Investor Protection Publicity Day on May 15, we organized the “Shareholders Are Here” event jointly with Everbright Securities to attract investors’ participation in the education on rational investing through short videos and live broadcasts on all of the Company’s platforms, together with the active promotion by traditional media such as Hubei TV and China Business Network (CBN). As of December 31, 2024, we have exclusively sponsored CBN’s live broadcast of the Berkshire Hathaway Annual Shareholders Meeting for the fifth consecutive year. We produced the live broadcast program “Buffett and Seven Lunches”, which recorded a total online viewership of nearly 227 million.Business outlookThe chairman of the Board and chief executive officer of JF SmartInvest Holdings Ltd, Mr. Chen Wenbin said: "We will adhere to our principles of rational investing, value investing and long-term investing to help customers induce right investing concepts, practice investor education, fulfil corporate social responsibility and commit ourselves to promoting healthy development of the capital market in the long run. Looking forward to 2025, we, as a next-generation stock investing assistant, will continue to strengthen our competitiveness, solidify our market leadership and strive to make investing and wealth management easier yet more professional, and enhance the happiness of investing and wealth management. "About JF SmartInvest Holdings Ltd (Stock Code: 9636)JF SmartInvest Holdings Ltd is a new generation stock investment assistant. The Company is engaged in the provision of equity investment instruments, securities investment advisory, investor education and other services to individual investors. The products include stock quote software, stock learning machine, Stock Navigator, Super Investor and Jiuyao Stocks. The Company adopts the technology + investment research model, develops JF Robo-Advisor, FinSphere Agent, FinSphere Report and other products based on artificial intelligence (AI) and big data technology, which are applied to the industry in terms of innovative practice and scenario application.For enquiries, please contact:Financial PR (HK) LimitedEmail: ir@financialpr.hkTel: 852 2610 0846Fax: 852 2610 0842 Copyright 2025 ACN Newswire via SeaPRwire.com.

Kuala Lumpur/Bangkok/Singapore , Apr 3, 2025 - (ACN Newswire via SeaPRwire.com) - India is emerging as the world’s next manufacturing giant—yet global corporations still stumble at the entrance. Despite its $7.5 trillion growth trajectory, cost advantages, and policy incentives, there are still several obstacles in the way of building a long-lasting presence in India. A recent whitepaper titled “Why Do Global Manufacturers Struggle with India Market Entry” offers a data-driven blueprint for overcoming regulatory, supply chain, and regulatory obstacles in one of the world’s complex but most promising economies.Regional companies aiming to expand into India can find a powerful roadmap in SRKay Consulting Group’s latest release, “Why Do Global Manufacturers Struggle with India Market Entry” This comprehensive publication outlines the key challenges that often derail even the most experienced players—including regulatory red tape, infrastructure hurdles, intellectual property risks, pricing pressures, and workforce acquisition difficulties.The report dives deep into the root causes behind these obstacles, from fragmented supply chains to complex compliance landscapes, and presents a structured, four-pillar India entry strategy. Covering insights across seven key sectors, it serves as an essential guide for manufacturers seeking to build a resilient and scalable presence in the Indian market.Highlights & Strategic Takeaways:A Proven India Market Entry Framework: A four-pillar approach covering research, business setup, supply chain localisation, and long-term growth.Real Success Stories: What global giants like Apple, Hyundai, and IKEA won in India by adapting to local demand and operational realities.Insights for Emerging Market Entrants: UAE and Malaysia-based companies prioritise India’s growth and competitive costs, but face workforce, regulatory, and IP-related hurdles.Digital & Trade Enablers: How UPI, ONDC, and Free Trade Agreements (like CEPA and ECTA) are creating new competitive advantages for manufacturers.“India is not just a big market—it’s a complex one. For Southeast Asian companies, entering India without the right regulatory, supply chain, and cultural game plan is risky. This whitepaper is our answer to help them succeed,” said Alok Kumar, Founder & Managing DirectorThis whitepaper is an essential resource for business strategists assessing market viability or C-suite executives considering expansion to confidently and clearly navigate the India opportunity.Download the Whitepaper NowWhy Do Global Manufacturers Struggle with India Market EntryAbout SRKay Consulting GroupSRKay Consulting Group is a global consulting firm that helps companies expand into emerging markets like India through data-led strategies, market entry advisory, and operational consulting. With deep expertise in regulatory compliance, digital infrastructure, and supply chain localization, SRKay is the trusted partner for Southeast Asian firms entering India.For expert consultation and partnership opportunities, connect with:Komaldeep KaurEmail: Komal@mianext.com Copyright 2025 ACN Newswire via SeaPRwire.com.